Skip to content
Onpattro(patisiran)
Onpattro (patisiran) is an oligonucleotide pharmaceutical. Patisiran was first approved as Onpattro on 2018-08-10. It has been approved in Europe to treat familial amyloidosis.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Onpattro
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Patisiran sodium
Tradename
Company
Number
Date
Products
ONPATTROAlnylam PharmaceuticalsN-210922 RX2018-08-10
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
onpattroNew Drug Application2020-10-28
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
PATISIRAN SODIUM, ONPATTRO, ALNYLAM PHARMS INC
2025-08-10ODE-197
2023-08-10NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Patisiran Sodium, Onpattro, Alnylam Pharms Inc
110793792035-08-27DS, DPU-2378
81586012030-11-10DPU-2378
88026442030-10-21DPU-2378
81687752029-10-20DS, DPU-2378
87418662029-10-20U-2378
92341962029-10-20DPU-2378
102401522029-10-20DS, DPU-2378
80580692029-04-15DP
84923592029-04-15DP
88226682029-04-15DPU-2378
93644352029-04-15DPU-2378
111413782029-04-15DP
86420762027-10-03DP
83343732025-05-27DS, DP
99435382023-11-04DP
99435392023-11-04DP
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07X: Other nervous system drugs in atc
— N07XX: Other nervous system drugs in atc
— N07XX12: Patisiran
HCPCS
Code
Description
J0222
Injection, patisiran, 0.1 mg
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AmyloidosisD000686EFO_1001875E851—2—14
Familial amyloidosisD028226——3—14
Familial amyloid neuropathiesD028227E85.1——1—12
Amyloid neuropathiesD017772——1—12
Takotsubo cardiomyopathyD054549EFO_1002000I51.81——1—12
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PolyneuropathiesD011115EFO_0009562A69.221———12
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePATISIRAN
INNpatisiran
Description
Patisiran, sold under the brand name Onpattro, is a medication used for the treatment of polyneuropathy in people with hereditary transthyretin-mediated amyloidosis, a fatal rare disease that is estimated to affect 50,000 people worldwide.
Classification
Oligonucleotide
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1420706-45-1
RxCUI2053490
ChEMBL IDCHEMBL3989987
ChEBI ID—
PubChem CID—
DrugBankDB14582
UNII ID50FKX8CB2Y (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Onpattro - Alnylam Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,144 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
12,256 adverse events reported
View more details